7/25/2019 vanadyl

1/9

7/25/2019 vanadyl

2/9

7/25/2019 vanadyl

3/9

7/25/2019 vanadyl

4/9

7/25/2019 vanadyl

5/9

7/25/2019 vanadyl

6/9

7/25/2019 vanadyl

7/9

388 / Fawcett Farquhar Walker etal .

Table

1

Anthropometry, Body Composition DEXA),and Performance of Subjects

During the Clinical Trial of Oral Vanadyl Sulfate: Data are Mean

SD)

at 0 4 8

and 12Weeks

Vanadyl sulfate

n

= 15) Placebo

n

= 16)

Variable 0

4

8 12 0

4

8 12

Weight kg)

Sum of six

skinfolds mm)

Muscle girths cm)

Chest exp)

Chest insp)

Upper

rm

Thigh

Total fat

DEXA) kg)

Total lean

DEXA) kg)

Bench press kg)

10 RM

Leg extension kg)

10RM

RMt

p< .05, p< .01, Bonferroni inequality for comparison with 0 weeks. t p < .002 for

Treatment X Time interaction on repeated-measures ANOVA.

was no increase in lean body mass. Thus, this study did not support claims that

vanadyl sulfate is an anabolic agent.

Although major changes in body composition did not occur, both groups

showed small increases in body weight, which anthropometry suggests are due to

an increase in fat. The increase in weight and sum of six skinfolds was greater in the

VS

group after 4 weeks but similar in both groups after

12

weeks, suggesting that

vanadyl sulfate may promote deposition of body fat over a short period. The small

but significant increases in blood glucose and insulin observed in the V group

7/25/2019 vanadyl

8/9

7/25/2019 vanadyl

9/9